Last week, our BrightInsight team attended the AACC Annual Scientific Meeting and Clinical Lab Expo in Chicago. The annual AACC conference and exhibition draws over 20,000 attendees and 500 exhibitors showcasing the cutting-edge science and technology shaping the future of laboratory medicine. It was the ideal place to launch our digital Connected Diagnostics Platform, built specifically to meet the needs of in vitro diagnostics manufacturers.
This comprehensive, end to end platform is a one-stop solution for IVD manufacturers that streamlines workflows, accelerates revenue growth and drives innovation.
The global in vitro diagnostics market is projected to grow nearly 50 percent from $71 billion in 2022 to $107 billion by 2029. And since 60 and 70 percent of healthcare decisions are influenced by IVD test results, it’s critical for IVD manufacturers to manage their devices and data securely and reliably.
Our Connected Diagnostics Platform is four product types in one, and includes a proxy agent, analytics dashboards, integration middleware and portals (for the IVD manufacturers and the lab), all running on the compliant and secure BrightInsight Cloud. To learn more, read our CEO and co-founder Dr. Kal Patel’s article in Medical Design & Outsourcing.
We built the Connected Diagnostics Platform specifically because we were seeing demand for an end-to-end solution to help IVD manufacturers accelerate time to market and address compliance and security requirements. With an end-to-end platform, we are breaking down data silos created by working with multiple technology vendors, so that our IVD customers can realize greater efficiencies and speed to market. We are already working with a global IVD manufacturer and anticipate announcing more details on that partnership later this year.
It was a jam packed week on the show floor, at our client dinner, and sharing demos of our Connected Diagnostics Platform. You can preview the solution here.
Kal Patel and I had a great discussion with Leo O’Connor of LabPulse.com in a video interview on the conference floor. Listen to our conversation here for more about how our Connected Diagnostics Platform helps IVD manufacturers go from reactive to proactive with greater access and insights from real-world data.
Also at AACC, we announced the addition of Dr. Stephen Oesterle to our esteemed Advisory Council. His digital and medical device experience spans three decades and he will provide tremendous insights and advice to our team and clients. As he notes about his LinkedIn post, “I’m delighted to join the BrightInsight Advisory Council as the company introduces its latest digital platform innovation designed specifically to enable in vitro diagnostics manufacturers to accelerate time to market for digital solutions that will improve workflows. BrightInsight was a pioneer and is now a leading digital platform for medtech and biopharma, building regulated digital solutions that will enable greater data insights and analysis to drive improved outcomes.”
It's been an extremely busy summer for us at BrightInsight with two major launches, first in June at BIO with our digital Disease Management Solution, and last week’s Connected Diagnostics Platform launch at AACC, we expanded our Advisory Council with experts including Dr. Stephen Oesterle and Karl Hick, and are so excited to work with many of the world’s leading biopharma, medtech and IVD companies to build digital solutions designed to accelerate time to market and improve patient outcomes.